Monarch Partners Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Monarch Partners Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25,751	Closed	-$1.36M	–	237
2020 Q3	$1.36M	Buy	25,751 +11,550	+81%	+$713K	0.31%	94
2020 Q2	$870K	Hold	14,201	–	–	0.21%	100
2020 Q1	$803K	Buy	14,201 +2,815	+25%	+$160K	0.28%	70
2019 Q4	$648K	Buy	11,386 +2,850	+33%	+$151K	0.14%	127
2019 Q3	$457K	Buy	8,536 +1,010	+13%	+$58.8K	0.07%	155
2019 Q2	$449K	Buy	7,526 +1,230	+20%	+$77.4K	0.06%	149
2019 Q1	$392K	Sell	6,296 -2,960	-32%	-$196K	0.06%	162
2018 Q4	$561K	Buy	+9,256	New	+$553K	0.08%	145

Other funds holding BSTC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Monarch Partners Asset Management's BSTC Position: Q4 2020 in Review

Monarch Partners Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 25,751 shares — an estimated $1.36M sold.

Monarch Partners Asset Management first reported a position in BSTC in Q4 2018 and held it in 8 quarters. The position peaked at $1.36M in Q3 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

Monarch Partners Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
Monarch Partners Asset Management sold 25,751 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $1.36M.
Monarch Partners Asset Management first reported a position in BioSpecifics Technologies Corp. in Q4 2018 and held it in 8 quarters.
Monarch Partners Asset Management's BioSpecifics Technologies Corp. position peaked at $1.36M in Q3 2020.
1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Monarch Partners Asset Management's 13F filing for Q4 2020, filed 4 Feb 2021.